glp3.wiki
Regulatory status

Editorially reviewed · Last updated September 8, 2026 · How we review

Survodutide vs Tirzepatide (Zepbound): Glucagon vs GIP as the Second Target

Part of Weight Loss Drug Comparison Index.

Survodutide vs Tirzepatide (Zepbound): Glucagon vs GIP as the Second Target

Tirzepatide is approved; survodutide remains investigational. Both activate GLP-1 receptors, but tirzepatide also activates GIP receptors and survodutide activates glucagon receptors. That distinction is biologically interesting, but it does not by itself establish which drug is better for weight loss or liver disease.
Survodutide now has published Phase 3 obesity results: SYNCHRONIZE-1 reported 13.0% mean weight loss at 76 weeks with 6 mg under the treatment-regimen estimand, versus 5.4% with placebo. Tirzepatide 15 mg reported 20.9% at 72 weeks under SURMOUNT-1’s treatment-regimen estimand. These are separate trials, not a direct comparison. Reviewed September 8, 2026.

Side-by-Side Comparison

FeatureSurvodutideTirzepatide
DeveloperBoehringer Ingelheim / Zealand PharmaEli Lilly
ReceptorsGLP-1 + glucagonGLP-1 + GIP
AdministrationWeekly study injectionWeekly prescription injection
Selected obesity dose6 mg in SYNCHRONIZE-115 mg in SURMOUNT-1
Weight loss, treatment-regimen analysis13.0% at 76 weeks20.9% at 72 weeks
Liver evidenceBiopsy-based MASH improvement and MRI fat studiesBiopsy-based MASH resolution in SYNERGY-NASH
U.S. statusInvestigational; Phase 3 results publishedZepbound and Mounjaro approved for their labeled indications
Survodutide Phase 3 publication, SURMOUNT-1 publication.

How the Mechanisms Differ

Tirzepatide: GLP-1 + GIP

Tirzepatide activates both incretin receptors, affecting glucose-dependent insulin secretion and food intake. Its clinical results reflect the whole molecule and regimen. They do not quantify a separate GIP contribution or prove that resting energy expenditure never changes.

Survodutide: GLP-1 + Glucagon

Glucagon signaling is involved in hepatic metabolism and can affect energy expenditure. Survodutide combines that activity with GLP-1 activity. Preclinical mechanisms are not a measurement of how many additional calories a treated person burns, nor proof of a liver advantage over tirzepatide.

Why This Matters

A receptor list cannot rank medicines. Dose in milligrams is also not comparable across different molecules: 15 mg of tirzepatide is not inherently a stronger dose than 6 mg of survodutide. Clinical endpoints, adverse events, and the populations studied are more useful for comparing the evidence.

Weight Loss Comparison

Swipe sideways to see every column.

Drug and trialDurationParticipantsTreatment-regimen resultEfficacy result
Survodutide 6 mg, SYNCHRONIZE-176 weeks72513.0% vs 5.4% placeboUp to 16.6% vs 3.2% placebo
Tirzepatide 15 mg, SURMOUNT-172 weeks2,53920.9% vs 3.1% placebo22.5% vs 2.4% placebo

What the Numbers Show

Treatment-regimen analyses estimate effects regardless of treatment discontinuation; efficacy analyses address a different question about treatment adherence. Do not compare the larger efficacy number for one drug with the treatment-regimen number for another without identifying that difference.

Survodutide’s older Phase 2 result of up to 18.7% at 46 weeks was an actual-treatment analysis. The planned-treatment result at 4.8 mg was 14.9%. It should not be presented as a guaranteed precursor to a higher Phase 3 result.

Tirzepatide’s reported average is numerically larger in these separate studies. Differences in participants, placebo response, treatment exposure, and handling of missing data prevent a causal ranking. No direct survodutide-versus-tirzepatide result was identified in this review.

Sources: SYNCHRONIZE-1, manufacturer’s Phase 3 efficacy analysis, SURMOUNT-1.

MASH and Liver Fat: Different Endpoints

Both drugs have encouraging liver results, but MASH improvement, MASH resolution, fibrosis improvement, and MRI liver-fat reduction are different outcomes.

Survodutide MASH Data (Phase 2)

The 293-participant, 48-week study included biopsy-confirmed MASH with F1–F3 fibrosis. MASH improvement without worsening fibrosis occurred in 47%, 62%, and 43% at 2.4, 4.8, and 6 mg, versus 14% with placebo. This primary endpoint was improvement, not resolution. An “83% resolution” summary does not describe this primary outcome. Primary publication.

Tirzepatide MASH Data (SYNERGY-NASH, Phase 2b)

The 190-participant study enrolled people with biopsy-confirmed MASH and F2–F3 fibrosis for 52 weeks.

DoseMASH resolution without worsening fibrosisFibrosis improvement without worsening MASH
15 mg62%51%
10 mg56%51%
5 mg44%55%
Placebo10%30%
These are the publication’s main estimates, including its handling of missing biopsy results; they differ from the separate efficacy-estimand figures sometimes quoted in press releases. SYNERGY-NASH publication.

Comparing the MASH Results

The different endpoints and fibrosis populations prevent a simple percentage ranking. Glucagon activity does not prove survodutide is superior for MASH. Likewise, a reduction in liver fat does not establish fibrosis reversal or fewer liver-related complications. Larger and longer liver trials are needed for those questions.

Survodutide’s 2026 MRI analyses add evidence of reduced visceral and liver fat, but selected on-treatment substudy findings should not be treated as outcomes for every randomized participant or proof of muscle preservation.

Side Effects Comparison

In SYNCHRONIZE-1, gastrointestinal adverse events occurred in 80.9% at 3.6 mg and 89.7% at 6 mg, versus 47.9% with placebo. They were usually mild or moderate. The manufacturer reported discontinuation because of GI events in 19% across survodutide doses versus 2.9% with placebo. This is specifically a GI-discontinuation figure, not an all-adverse-event rate.

In SURMOUNT-1, discontinuation because of any adverse event ranged from 4.3% to 7.1% across tirzepatide doses, including 6.2% at 15 mg. These are different discontinuation categories and different trials.

The Discontinuation Rate Gap

Survodutide’s earlier Phase 2 study had a 24.6% adverse-event discontinuation rate across active doses versus 3.9% with placebo. The Phase 3 findings now add evidence beyond that earlier study. Escalation, exposure, and populations can affect discontinuation, but a cross-trial comparison cannot establish how much of the gap those factors explain or promise that slower escalation fixes it.

Survodutide Phase 3 safety report, manufacturer’s GI-discontinuation report, SURMOUNT-1.

Where Retatrutide Fits

Retatrutide activates GLP-1, GIP, and glucagon receptors. It remains investigational. TRIUMPH-1 reported 28.3% weight loss at 80 weeks with 12 mg under its efficacy estimand, and 25.0% under its treatment-regimen estimand. Primary report.

Its earlier MRI liver-fat substudy measured a different outcome from biopsy-based MASH trials. Neither a three-receptor mechanism nor a larger number from another study establishes superiority across weight, liver disease, and safety.

See retatrutide vs tirzepatide and retatrutide vs survodutide.

Regulatory Status and Availability

Tirzepatide is available by prescription as Zepbound or Mounjaro for their labeled indications. Survodutide is not FDA-approved and has no established commercial price or launch date. A positive Phase 3 publication does not guarantee approval.

For current indications, see the Zepbound label and Mounjaro label. For investigational access, use registered studies and study-site contacts rather than a seller’s product listing.

Frequently Asked Questions

Is survodutide better than tirzepatide for weight loss?

A direct advantage has not been established. SYNCHRONIZE-1 reported 13.0% at 76 weeks for survodutide 6 mg under its treatment-regimen estimand; SURMOUNT-1 reported 20.9% at 72 weeks for tirzepatide 15 mg under its corresponding analysis. Different study populations and designs prevent interpreting that gap as a head-to-head result.

Is survodutide better than tirzepatide for fatty liver disease (MASH)?

That is unproven. Survodutide’s Phase 2 primary endpoint was MASH improvement without worsening fibrosis, whereas SYNERGY-NASH measured MASH resolution without worsening fibrosis. Comparing “83% versus 73.3% resolution” misstates the survodutide endpoint. Neither receptor biology nor those separate trials establishes a superior MASH treatment.

What is the difference between glucagon and GIP?

GIP is an incretin involved in glucose-dependent insulin secretion and metabolic signaling. Glucagon regulates hepatic fuel handling and can affect energy expenditure. Survodutide pairs glucagon with GLP-1 activity; tirzepatide pairs GIP with GLP-1. These mechanisms alone cannot predict the clinical winner.

Can I get survodutide now?

Survodutide is investigational and cannot be prescribed as an FDA-approved medicine. Trial eligibility and recruitment depend on the study and site. Tirzepatide is the approved prescription option of these two.

How does survodutide vs tirzepatide vs retatrutide compare?

Survodutide targets GLP-1 and glucagon; tirzepatide targets GLP-1 and GIP; retatrutide targets all three. Only tirzepatide is FDA-approved. Each has a different evidence base, and separate weight-loss or liver-study percentages do not prove that one molecule combines every benefit of the others.

Why does survodutide have a higher discontinuation rate?

GI tolerability has been a challenge in both Phase 2 and Phase 3 survodutide studies. Escalation and study design may matter, but there is no direct trial showing how much they explain differences from tirzepatide. Keep GI-related and all-adverse-event discontinuation rates distinct.

Will survodutide be approved before retatrutide?

No approval order is established. Survodutide has published SYNCHRONIZE-1 Phase 3 results, and retatrutide has multiple Phase 3 readouts. Lilly plans a Q1 2027 U.S. retatrutide submission, which is not an FDA approval date.

Sources

  1. Le Roux, C.W., et al. (2024). Survodutide for the treatment of obesity: a randomised, double-blind, placebo-controlled, dose-finding Phase 2 trial. The Lancet Diabetes & Endocrinology. ClinicalTrials.gov (NCT04667377)
  2. Jastreboff, A.M., et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2206038
  3. Loomba, R., et al. (2024). Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). New England Journal of Medicine. DOI: 10.1056/NEJMoa2401943
  4. Boehringer Ingelheim. Survodutide Phase 2 MASH trial results. Boehringer Ingelheim
  5. Eli Lilly. (2025). TRIUMPH-4 results. Press release
  6. Eli Lilly. (2024). Tirzepatide was superior to placebo for MASH resolution (SYNERGY-NASH). Press release
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Survodutide is an investigational compound that has not been approved by the FDA or any regulatory authority. Tirzepatide is FDA-approved as Zepbound (obesity) and Mounjaro (type 2 diabetes). Always consult a healthcare provider before starting any medication. This site is not affiliated with Boehringer Ingelheim, Zealand Pharma, Eli Lilly, or any pharmaceutical manufacturer.
How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Survodutide remains investigational. Tirzepatide has FDA-approved products, including Mounjaro and Zepbound, with different indications.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all compare topics →